 |
|
|
| |
C-EDGE CO-STAR: Interim Results From the 3-year Follow-up Trial on Risk Factors and Rate of Reinfection in Patients on Opiate Agonist Therapy Previously Treated With Elbasvir/Grazoprevir for 12 Weeks
|
| |
| |
Reported by Jules Levin
AASLD 2016 Nov 11-15 Boston, MA
Dore GJ1; Grebely J1; Altice F2; Litwin AH3; Dalgard O4; Gane EJ5; Shibolet O6; Luetkemeyer A7; Nahass R8; Peng C-Y9; Conway B10; Iser DM11; Huang H-C12; Gendrano IN12; Kelly MM12; Hwang P12; Robertson M12; Wahl J12; Barr E12; Platt HL12
1The Kirby Institute, University of New South Wales, Sydney, NSW, Australia;
2Yale University School of Medicine, New Haven, CT, USA; 3Montefiore Medical
Center and Albert Einstein College of Medicine, Bronx, NY, USA; 4Institute of Clinical Medicine, Oslo, Norway; 5Auckland Clinical Studies, Auckland, New Zealand; 6Tel-Aviv Medical Center, Tel Aviv, Israel; 7University of California, San Francisco, San Francisco, CA, USA; 8ID Care, Hillsborough, NJ, USA; 9China Medical University Hospital, Taichung, Taiwan; 10Vancouver Infectious Diseases Centre, Vancouver, BC, Canada; 11St. Vincent's Hospital; Melbourne, VIC, Australia; 12Merck & Co., Inc., Kenilworth, NJ, USA
|
| |
|
|
|
|
|
